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a  b  s  t  r  a  c  t
Background:  The  aim  of  this  study  was  to investigate  a useful  cardiac  biomarker  for  predicting  echocar-
diographic  right  ventricular  (RV)  dysfunction  in patients  with  acute  pulmonary  embolism  (APE).
Methods:  A  total  of 84  patients  with  APE  were  divided  into  two  groups:  patients  with  RV  dysfunction
(group  I, n = 51,  61.8 ±  15.1  years)  versus  without  RV  dysfunction  (group  II,  n  = 33, 66.8  ±  13.6 years).
Cardiac  biomarkers  were  compared  between  the  groups.
Results:  The  level  of  N-terminal  pro-brain-type  natriuretic  peptide  (NT-proBNP),  cardiac  speciﬁc  tro-
ponin T (cTnt),  and  I (cTni)  was  signiﬁcantly  elevated  in group  I compared  to  group  II, but the  level  of
creatine  kinase  and  high-sensitivity  C-reactive  protein  was  not  different.  By  receiver  operating  charac-
teristic  curve  analysis,  the  area  under  the  curve  to predict  RV  dysfunction  was  0.912  for NT-proBNP,
0.797  for  cTnt,  and  0.766  for  cTni.  The  optimal  cut-off  value  to predict  RV dysfunction  was  620.0  pg/mL
for  NT-proBNP  (sensitivity:  90.2%,  speciﬁcity:  75.8%),  0.016  ng/mL  for cTnt  (sensitivity:  82.4%,  speci-
ﬁcity:  78.8%),  and  0.055  ng/mL  for cTni  (sensitivity:  86.3%,  speciﬁcity:  66.7%).  NT-proBNP  >  620  pg/mL
and  cTnt  >  0.016  ng/mL  were  independent  predictors  of  RV  dysfunction  on  multivariate  analysis  after
adjustment  for  the  baseline  characteristics.
Conclusions:  NT-proBNP,  cTnt,  and  cTni  were  signiﬁcant  serologic  predictors  of  RV  dysfunction  in  APE.
Measurements  of NT-proBNP,  cTnt,  and  cTni  are  simple  and  useful  in  the  risk  stratiﬁcation  or  treatment
of  APE.
©  2012  Japanese  College  of Cardiology.  Published  by  Elsevier  Ltd.  All rights  reserved.ntroduction
Acute pulmonary embolism (APE) is not uncommon in clini-
al practice, and the mortality of APE is still high despite advances
n diagnostic modalities and therapeutic options [1–3]. It has
een proved that patients with massive APE, deﬁned by systemic
ypotension, should be treated with thrombolysis or embolectomy
4,5].
Right ventricular (RV) dysfunction is a well-known predictor
f early death, and thus early identiﬁcation of RV dysfunction is
ritical in the risk stratiﬁcation or management of APE [6–10].
ransthoracic echocardiography (TTE) has been used as a method
f choice to identify the patients with RV dysfunction [11].
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ttp://dx.doi.org/10.1016/j.jjcc.2012.07.006Cardiac biomarkers such as troponin and N-terminal pro-brain-
type natriuretic peptide (NT-proBNP) are known to be useful not
only in the diagnosis, but also in the risk stratiﬁcation of various car-
diac diseases [12,13]. Furthermore, recent studies have suggested
that cardiac biomarkers are associated with an increased risk of
mortality in patients with APE, even in hemodynamically stable
patients [14–18],  and thus cardiac biomarkers are useful in the risk
stratiﬁcation of APE. It has been suggested that cardiac biomarkers
are associated with the presence of RV dysfunction on echocardiog-
raphy. Although several studies have been conducted to prove the
relationship between cardiac biomarkers and RV dysfunction on
echocardiography [19–23,10,24], the comparisons among cardiac
biomarkers in the prediction of RV dysfunction and the optimal
cutoff values of cardiac biomarkers to predict RV dysfunction were
poorly evaluated.Therefore, the aim of the present study was  to investigate the
most useful serologic predictors of RV dysfunction and to investi-
gate the optimal cutoff values of cardiac biomarkers to predict RV
dysfunction in patients with APE.
vier Ltd. All rights reserved.

























































Group I (n = 51) Group II (n = 33) p-Value
Age (years) 61.8 ± 15.1 66.8 ± 13.6 0.128
Females (%) 31 (60.8) 20 (60.6) 0.987
SBP  (mmHg) 113.1 ± 19.8 135.2 ± 16.7 <0.001
DBP  (mmHg) 72.7 ± 13.7 82.5 ± 10.5 <0.001
Heart rate (beat/min) 88.1 ± 13.9 81.7 ± 10.6 0.028
Clinical symptoms
Dyspnea (NYHA class) 2.8 ± 1.0 1.9 ± 0.9 <0.001
Chest pain (%) 21 (41.2) 12 (36.4) 0.659
Hemoptysis (%) 2 (3.9) 6 (18.2) 0.069
Syncope (%) 10 (19.6) 4 (12.1) 0.369
Cyanosis (%) 5 (9.8) 0 (0.0) 0.064
Predisposing conditions
Previous DVT or PTE (%) 6 (11.8) 5 (15.2) 0.653
Immobilization (%) 7 (13.7) 5 (15.2) 0.855
Smoking (%) 10 (19.6) 12 (36.4) 0.088
Obesity (%) 12 (23.5) 7 (21.2) 0.804
Malignancy (%) 6 (12.2) 4 (12.1) 0.961
Thrombophilic condition (%) 1 (2.0) 1 (3.0) 0.754
Pregnancy (%) 1 (2.0) 0 (0.0) 0.418
SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, New York HeartH.S. Choi et al. / Journal of
aterials and methods
tudy design and population
The present study was a single center retrospective obser-
ational study, and the study protocol was approved by the
nstitutional Review Board of Chonnam National University Hos-
ital.
The diagnosis of APE was conﬁrmed by the presence of ﬁlling
efects within the pulmonary arterial systems on helical computed
omographic pulmonary angiography (CTPA) in patients who  pre-
ented with dyspnea, tachycardia, chest discomfort, or hemoptysis.
rom 2004 to 2007, a total of 101 consecutive patients with APE
ere included initially. Of these, 17 patients were excluded from
he study; nine patients with lack of biomarker tests; 3 patients
ith combined left heart failure; 2 patients with known cor pul-
onale; 2 patients without initial echocardiogram; 1 patient with
nd-stage renal disease. The remaining 84 patients with APE were
nrolled ﬁnally in the present study, and they were divided into two
roups based on the presence of RV dysfunction on echocardiogra-
hy: patients with RV dysfunction (group I, n = 51, 61.8 ± 15.1 years,
1 females) versus patients without RV dysfunction (group II, n = 33,
6.8 ± 13.6 years, 20 females). Obesity was deﬁned as body-mass
ndex > 27 kg/m2, and immobilization as prolonged bed rest associ-
ted with orthopedic surgery, major fracture, or cerebrovascular
ccidents, or prolonged sitting during travel. The thrombophilic
ondition was  deﬁned as the patients with known risk factors for
enous thrombosis such as factor V leiden, protein C or S deﬁciency,
nti-phospholipid syndrome, or essential thrombocytosis.
TE examination
TTE was performed within 6 h after diagnosis of APE by CTPA
or the risk stratiﬁcation or clinical decision-making of therapeutic
trategy.
The presence of RV dysfunction was conﬁrmed only based on the
chocardiographic ﬁndings in the present study. The demonstra-
ion of RV free wall hypokinesia or akinesia on echocardiographic
xamination was considered as the deﬁnite diagnosis of RV dys-
unction in patients with APE. RV enlargement, deﬁned by the ratio
f RV to LV size more than 1 in apical 4 chamber view without obvi-
us causes, accompanied by pulmonary hypertension in patients
ith APE was also considered as RV dysfunction in the present
tudy [11]. Fractional area change (FAC), tricuspid annular plane
ystolic excursion (TAPSE), and RV systolic pressure were also mea-
ured as the additional parameters of RV function according to the
urrent guideline of the American Society of Echocardiography [25].
ccentricity index (EI) which reﬂected the degree of RV pressure
verload was measured at the parasternal short-axis view during
oth end-systole and end-diastole. EI was calculated by measuring
he ratio D2/D1, where D1 is the antero-posterior dimension and
2 is the transverse dimension of the left ventricle.
easurement of cardiac biomarkers
NT-proBNP, cardiac speciﬁc troponin T (cTnt), I (cTni), creatine
inase (CK), and MB  fraction of CK (CK-MB), and high-sensitivity
-reactive protein (hsCRP) were measured as cardiac biomarkers
ithin 1 h after the diagnosis of APE and before the initiation of
hrombolytic therapy.
Serum NT-proBNP was measured using an electrochemilumi-
escence sandwich immunoassay method for NT-proBNP with an
lecsys 2010 analyzer (Roche Diagnostics, Basel, Switzerland). This
ethod has high sensitivity and speciﬁcity, and large detection
ange. The analytic range of the NT-proBNP assay extends from 5
o 35,000 pg/mL. The reference value varies according to age andAssociation; DVT, deep vein thrombosis; PTE, pulmonary thromboembolism.
gender, and <88 pg/mL for men  and <153 pg/mL for women  in our
institution. cTnt was  measured using electrochemiluminescence
sandwich immunoassay method with an Cobas e 411 (Roche Diag-
nostics), and the reference range for cTnt was <0.1 ng/mL. cTni was
also measured using one step Enzyme Immunoassay with a Dimen-
sion RxL Max  (Siemens, Munich, Germany), and the reference
range for cTni was <0.05 ng/mL. And hsCRP was measured by the
immunoturbidimetric CRP-Latex (II) high-sensitivity assay using an
Olympus 5431 autoanalyzer with reference range of <0.5 mg/dL.
Statistical analysis
The Statistical Package for Social Sciences for Windows (version
17.0, Chicago, IL, USA) was used for statistical analyses. Data were
expressed as mean ± standard deviation for continuous variables
and percentage for categorical data.
Chi-square test was  used to compare differences in categori-
cal values between the two  groups. Independent t-test was  used
to compare differences in continuous variables. Receiver operating
characteristic (ROC) curve analysis was  conducted to identify the
optimal cut-off value of biomarkers to predict RV dysfunction. Cor-
relation analysis between cardiac biomarkers and the parameters
of RV dysfunction was  established by the Pearson correlation. To
identify the independent biochemical predictors of RV dysfunction,
multivariate logistic regression analysis adjusted by the baseline
clinical characteristics including age, sex, blood pressure, heart rate,
and creatinine level was applied to the signiﬁcant cardiac biomark-
ers associated with RV dysfunction. A p-value less than 0.05 was
considered as statistically signiﬁcant.
Results
Baseline clinical characteristics
Baseline clinical characteristics are summarized in Table 1. Age,
sex, and the predisposing conditions were not different between
the groups. Systolic and diastolic blood pressures were signiﬁcantly
lower, and the heart rate was  signiﬁcantly higher in group I than
in group II. The degree of dyspnea was signiﬁcantly more severe in
group I than in group II.
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Table  2
Echocardiographic ﬁndings of the patients.
Group I (n = 51) Group II (n = 33) p-Value
LVEDD (mm) 40.5 ± 6.4 46.4 ± 5.1 <0.001
LVESD (mm) 26.6 ± 5.2 30.1 ± 4.9 0.003
LVEF (%) 63.8 ± 8.5 64.6 ± 6.9 0.638
E  (m/s) 0.53 ± 0.12 0.65 ± 0.17 0.001
A  (m/s) 0.77 ± 0.10 0.82 ± 0.13 0.046
DT  (s) 190.5 ± 32.6 230.2 ± 78.5 0.002
Em  (m/s) 6.0 ± 1.0 6.4 ± 1.2 0.156
E/Em 8.9 ±  2.2 10.8 ± 3.6 0.004
LA  dimension (mm) 31.7 ± 6.2 35.4 ± 4.7 0.004
RVSP (mmHg) 55.7 ± 10.6 42.9 ± 10.2 <0.001
RVEDD/LVEDD 0.88 ± 0.21 0.61 ± 0.11 <0.001
RV  FAC (%) 27.8 ± 11.6 53.4 ± 13.1 <0.001
TAPSE (mm)  11.4 ± 4.4 16.4 ± 4.4 <0.001
EI  (diastolic) 1.27 ± 0.21 1.01 ± 0.08 <0.001
EI  (systolic) 1.35 ± 0.31 1.07 ± 0.07 <0.001
LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic
dimension; LVEF, left ventricular ejection fraction; E, early diastolic velocity of mitral
inﬂow; A, late diastolic velocity of mitral inﬂow; DT, deceleration time of mitral
































Fig. 1. Receiver operating characteristic curve analysis to predict right ventricular
dysfunction on echocardiography. Asterisks indicate the optimal cut-off point of
each variable. NT-proBNP, N-terminal-pro-B-type natriuretic peptide; cTnt, cardiac
speciﬁc troponin T; cTni, cardiac speciﬁc troponin I.
Table 4
Correlation between cardiac biomarkers and the echocardiographic indices of right
ventricular dysfunction.
Variables NT-proBNP cTnt CTni
RVEDD/LVEDD ratio 0.651** 0.528** 0.469**
EI (systolic) 0.709** 0.658** 0.600**
EI (diastolic) 0.668** 0.548** 0.493**
TAPSE −0.440** −0.326* −0.220*
FAC −0.655** −0.406** −0.332**
SPAP 0.634** 0.364** 0.180
NT-proBNP, N-terminal-pro-B-type natriuretic peptide; cTnt, cardiac speciﬁc tro-
ponin T; cTni, cardiac speciﬁc troponin I; RVEDD, right ventricular end-diastolic
dimension; LVEDD, left ventricular end-diastolic dimension; EI, eccentricity index;
TAPSE, tricuspid annular plane systolic excursion; FAC, fractional area change; SPAP,
systolic pulmonary artery pressure.
* Numeric values represent the Pearson correlation coefﬁcient: p < 0.05.ight  ventricular systolic pressure; RVEDD, right ventricular end-diastolic dimen-
ion; FAC, fractional area change; TAPSE, tricuspid annular plane systolic excursion;
I,  eccentricity index.
TE ﬁndings
Baseline TTE ﬁndings are summarized in Table 2. LV and left
trial chamber sizes were signiﬁcantly smaller, and RV systolic
ressure was signiﬁcantly greater in group I than in group II. Early
E) and late diastolic velocities (A) of mitral inﬂow and early dias-
olic septal annular velocity (Em) were signiﬁcantly lower, and
eceleration time of mitral inﬂow was signiﬁcantly shorter in group
 than in group II. The indices of RV dysfunction were more signiﬁ-
antly impaired in group I than in group II.
ardiac biomarkers and RV dysfunction
The results of cardiac biomarkers are summarized in Table 3.
he levels of NT-proBNP and cardiac troponins were signiﬁcantly
levated in group I compared to group II. However, the levels of
sCRP and CK were not different between the groups.
By ROC curve analysis, the area under the curve to predict RV
ysfunction on echocardiography was 0.912 for NT-proBNP, 0.797
or cTnt, and 0.766 for cTni. The optimal cut-off value to pre-
ict RV dysfunction was 620.0 pg/mL for NT-proBNP (sensitivity:
0.2%, speciﬁcity: 75.8%), 0.016 ng/mL for cTnt (sensitivity: 82.4%,
peciﬁcity: 78.8%), and 0.055 ng/mL for cTni (sensitivity: 86.3%,
peciﬁcity: 66.7%) (Fig. 1).
Correlation between cardiac biomarkers and the parameters of
V dysfunction was measured by Pearson correlation and summa-
ized in Table 4. NT-pro-BNP, cTnt, and cTni showed signiﬁcant
ositive correlation with RVEDD/LVEDD ratio, systolic and dias-
olic EI, and SPAP. NT-pro-BNP, cTnt, and cTni showed signiﬁcant
egative correlation with TAPSE.
able 3
ardiac biomarkers and right ventricular dysfunction.
Group I (n = 51) Group II (n = 33) p-Value
NT-proBNP (pg/mL) 4079.8 ± 3127.9 638.1 ± 759.9 <0.001
cTnt  (ng/mL) 0.20 ± 0.30 0.05 ± 0.11 0.002
cTni  (ng/mL) 0.77 ± 1.48 0.21 ± 0.47 0.015
hsCRP (mg/dL) 3.1 ± 3.3 2.5 ± 3.2 0.364
CK  (U/L) 119.5 ± 84.5 117.1 ± 99.6 0.905
CK-MB (U/L) 8.7 ± 4.4 8.0 ± 5.1 0.494
T-proBNP, N-terminal-pro-B-type natriuretic peptide; cTnt, cardiac speciﬁc tro-
onin T; cTni, cardiac speciﬁc troponin I; hsCRP, high-sensitivity C-reactive protein;
K, creatine kinase; CK-MB, MB  fraction of CK.** Numeric values represent the Pearson correlation coefﬁcient: p < 0.01.
Multivariate logistic regression analysis was  performed to iden-
tify the independent biochemical predictors of RV dysfunction.
NT-proBNP > 620 pg/mL, cTnt > 0.016 ng/mL, and age were signiﬁ-
cant independent predictors of RV dysfunction after the adjustment
for the baseline clinical characteristics (Table 5).Table 5
Predictors of echocardiographic right ventricular dysfunction by multivariate logis-
tic  regression analysis.
Variable Odds ratio 95% CI p-Value
NT-proBNP > 620 pg/mL 5.038 2.352–9.598 <0.001
cTnt > 0.016 ng/mL 5.582 3.786–8.232 0.003
cTni  > 0.055 ng/mL 1.403 0.109–18.182 0.796
Age  1.080 1.020–1.144 0.009
Serum creatinine level 1.349 0.223–8.130 0.744
Female 0.939 0.171–5.157 0.942
CI, conﬁdence interval; NT-proBNP, N-terminal-pro-B-type natriuretic peptide;
cTnt, cardiac speciﬁc troponin T; cTni, cardiac speciﬁc troponin I.
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Table  6
Cardiac biomarkers and in-hospital mortality.
No death (n = 78) Death (n = 6) p-Value
NT-proBNP (pg/mL) 2425.2 ± 2818.6 6660.2 ± 2582.7 0.001
cTnt  (ng/mL) 0.13 ± 0.25 0.34 ± 0.24 0.049
cTni  (ng/mL) 0.54 ± 1.26 0.77 ± 0.29 0.649
hsCRP (mg/dL) 2.8 ± 3.3 3.5 ± 2.8 0.607
CK  (U/L) 114.8 ± 91.7 167.8 ± 47.4 0.166
























NT-proBNP, N-terminal-pro-B-type natriuretic peptide; cTnt, cardiac speciﬁc tro-
onin T; cTni, cardiac speciﬁc troponin I; hsCRP, high sensitivity C-reactive protein;
K, creatine kinase; CK-MB, MB fraction of CK.
n-hospital mortality
Six patients (7.1%) died due to the consequences of APE during
ospitalization. The mortality rate was signiﬁcantly higher in group
 than in group II (11.8% versus 0.0%, p = 0.041).
The levels of NT-proBNP and cTnt were signiﬁcantly associated
ith in-hospital mortality in patients with APE, but the levels of
Tni, CK, and hsCRP were not associated with in-hospital mortality
Table 6).
By ROC curve analysis, the area under the curve to predict
n-hospital mortality was 0.870 for NT-proBNP and 0.865 for
Tnt. The optimal cut-off value to predict in-hospital mortality
as 2664.0 pg/mL for NT-proBNP (sensitivity: 100.0%, speciﬁcity:
6.7%), 0.09 ng/mL for cTnt (sensitivity: 100.0%, speciﬁcity: 76.9%)
Fig. 2).
iscussion
The present study comprehensively evaluated and compared
he roles of commonly used cardiac biomarkers in the risk stratiﬁ-
ation or evaluation of APE. The main ﬁnding of the present study
as that the levels of NT-proBNP and cardiac troponins were sig-
iﬁcant predictors of echocardiographic RV dysfunction, and the
evel of NT-proBNP and cTnt could predict in-hospital mortality
n patients with APE. The NT-proBNP showed best sensitivity and
ig. 2. Receiver operating characteristic curve analysis to predict in-hospital mor-
ality. Asterisks indicate the optimal cut-off point of each variable. NT-proBNP,
-terminal-pro-B-type natriuretic peptide; cTnt, cardiac speciﬁc troponin T.ology 60 (2012) 508–513 511
speciﬁcity to predict echocardiographic RV dysfunction, and cTnt
showed best sensitivity and speciﬁcity to predict in-hospital mor-
tality in patients with APE. In addition, the present study also
suggested the optimal cutoff value of NT-proBNP and cardiac tro-
ponins to predict echocardiographic RV dysfunction or in-hospital
death. Based on the results of the present study, it is expected
that simple measurements of cardiac biomarkers would be useful
to predict the presence of RV dysfunction, especially in hospitals
where the echocardiographic examinations or experts in echocar-
diography are not readily available.
RV dysfunction on echocardiography is an independent and
useful predictor of mortality in patients with APE, regardless of
hemodynamic status [1].  Thus, the early identiﬁcation of RV dys-
function is critical in the clinical decision-making of therapeutic
strategy in patients with APE. Echocardiography has been the
most accepted method for the detection of RV dysfunction. How-
ever, there are some limitations in the routine clinical use of
echocardiography in patients with APE. Because the results of
echocardiography largely depend on the experience of the operator,
an expert in echocardiography would be essential to identify the
patients with RV dysfunction accurately. Furthermore, echocardio-
graphy is not always readily available, especially in private clinics
or secondary hospitals or at nighttime. In contrast to echocardio-
graphic examination, cardiac biomarkers can be readily available
in all patients at any time without operator-dependent variabil-
ity. Therefore, the measurement of cardiac biomarkers would be
a simple and useful method as an alternative to echocardiogra-
phy.
NT-proBNP is a 76-amino acid N-terminal fragment of proBNP
and released 1:1 fashion with BNP. It is released from ventricu-
lar cardiac myocytes in response to ventricular volume or pressure
overload [17]. Because RV dysfunction is usually accompanied by
RV volume or pressure overload, BNP or NT-proBNP could be a use-
ful biomarker of RV dysfunction if there are no other reasons for BNP
elevation, such as left heart failure or renal failure. In the present
study, the level of NT-proBNP showed good sensitivity and speci-
ﬁcity to predict RV dysfunction and in-hospital mortality in patients
with APE, regardless of hemodynamic status. Some of the previous
studies also demonstrated the association between the level of BNP
and echocardiographic RV dysfunction and suggested the optimal
cutoff values to predict RV dysfunction. Krüger et al. [19] suggested
that a BNP > 90 pg/mL could predict RV dysfunction, but the sensi-
tivity was  relatively low (64%) despite the reasonable speciﬁcity
(94%). Furthermore, BNP level was  not a predictor of in-hospital
complications and mortality in their study. In the study of Yardan
et al. [22], however, the level of BNP could predict the presence
of RV dysfunction with better sensitivity (93.8%) and speciﬁcity
(91.7%), even though they used the same optimal cut-off value of
BNP (>90 pg/mL). Pieralli et al. [23] also reported similar results
that the level of BNP could predict RV dysfunction with good sen-
sitivity (86%) and speciﬁcity (100%), and the level of BNP was  also
a predictor of in-hospital complications. The clinical signiﬁcance of
NT-proBNP to predict RV dysfunction or prognosis in patients with
APE has been proved to be similar to those of BNP [10,24]. However,
the optimal cutoff value for NT-proBNP to predict RV dysfunction or
mortality is poorly evaluated, and thus the authors want to evaluate
the optimal cutoff value of NT-proBNP to predict RV dysfunction. In
the present study, the level of NT-proBNP > 620 pg/mL could predict
the presence of RV dysfunction with relatively acceptable sensitiv-
ity (90.2%) and speciﬁcity (75.8%) to use in clinical practice, and
the level of NT-proBNP also could predict in-hospital mortality in
patients with APE.Cardiac-speciﬁc troponins, cTnt and cTni, are reliable mark-
ers of myocardial injury and known to be associated with RV
dysfunction or outcomes [26–28],  but the optimal cut-off values
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tudy suggested the optimal cut-off value to predict RV dysfunc-
ion or in-hospital mortality in patients with APE. According to
he results of the present study, among cardiac biomarkers, both
Tnt and NT-proBNP were useful markers of in-hospital mortality,
ut cTni was not a predictor of in-hospital mortality even though
he absolute value of cTni was higher in the dead than in the sur-
ivors. The reason why cTnt may  predict in-hospital death, but not
Tni is unclear. Considering the difference in the absolute value of
Tni between the dead and the survivors, the small number of the
tudy population would be one possible explanation. cTnt was not
easured by the highly sensitive method, but by the conventional
ethod in the present study. However, recent studies have sug-
ested that the measurement of highly sensitive cTnt would be a
ore sensitive and speciﬁc method for diagnosing acute coronary
yndrome than the conventional method [29], and highly sensi-
ive cTnt correlated with ventricular hypertrophy in patients with
ssential hypertension [30] and cardiac dysfunction evaluated by
chocardiography and natriuretic peptide in patients with heart
ailure [31]. To clarify the association between highly sensitive cTnt
nd echocardiographic parameters of RV dysfunction in patients
ith APE, further studies should be conducted in the near future.
The role of other cardiac biomarkers, such as CRP or CK-MB, in
PE was evaluated in some studies. CRP is a well known biomarker
or cardiovascular disease or events in various clinical settings
32,33], but the role of CRP in the prediction of RV dysfunction
r mortality in APE was poorly evaluated. The recent study of
bul et al. suggested that CRP would be a predictor of mortality
n patients with APE [34]. However, the results of the present study
uggested that CRP was not a predictor of RV dysfunction or mor-
ality in patients with APE. Therefore, a larger randomized clinical
tudy will be needed in the future to elucidate the role of CRP in APE.
lthough a few studies suggested that CK-MB was a predictor of RV
ysfunction [35] or mortality [36], CK-MB was neither a predictor
f RV dysfunction nor mortality of APE in the present study.
Although the LV systolic function as measured by EF was  not
ifferent, the parameters of diastolic function were signiﬁcantly
ifferent between the groups. E, A, Em,  and E/Em were signiﬁcantly
ower in patients with RV dysfunction than without RV dysfunction.
he reason for the lower E velocity in patients with RV dysfunction
ight be explained by the fact that the decreased RV function and
hrombi within pulmonary vasculatures may  induce LV preload
eduction. The decreased RV wall motion may  induce decreased
eptal wall motion and thus Em would become lower in patients
ith RV dysfunction than without RV dysfunction. E/Em was  sig-
iﬁcantly lower in patients with RV dysfunction than without RV
ysfunction in the present study. From this observation, it is sug-
ested that the LV preload might be more severely affected by RV
ysfunction than the septal wall motion.
The present study has several potential limitations. First, the
resent study is not a randomized controlled prospective study,
nd thus has all the limitations of a retrospective study. Second,
lthough the blood samples for cardiac biomarkers were taken as
oon as possible after the diagnosis of APE, the timing of blood sam-
lings might differ among the patients. Third, seventeen patients
ith APE were excluded from the present study for this and other
easons, and thus the results of the present study may  not reﬂect
ll characteristics of APE.
In conclusion, the results of the present study demonstrated
hat NT-proBNP and cardiac troponins were signiﬁcant predictors
f echocardiographic RV dysfunction in patients with APE. The
evels of cTnt and NT-proBNP were also signiﬁcant predictors of in-
ospital mortality. Therefore, the simple measurements of these
ardiac biomarkers would be helpful in clinical decision-making
r risk stratiﬁcation in patients with APE, especially in the clinics
here echocardiographic examinations or the experts in echocar-
iography were not readily available.ology 60 (2012) 508–513
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